NVS
NVS clinical trials: NOVARTIS AG
Every trial on ClinicalTrials.gov where NOVARTIS AG is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4,978
- Trials linked
- 3,516
- As lead sponsor
- 1,462
- As collaborator
- 42
- Primary completions as lead sponsor, next 90 days
NVS on the catalyst calendar · NVS registry changes
- Primary completion May 31, 2027Sponsor estimatePhase 1NCT05397496Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesNovartis Pharmaceuticals · B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2026ActualNo phase registeredNCT07844070A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After PregnancyNovartis Pharmaceuticals · Multiple SclerosisCompletedNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 17, 2028Sponsor estimatePhase 3NCT07850752A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNovartis Pharmaceuticals · IgA Nephropathy (IgAN)RecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2026ActualNo phase registeredNCT07468500Real World Adherence of PCSK9 Targeted TherapyNovartis Pharmaceuticals · Dyslipidemia, HypercholesterolemiaCompletedNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 18, 2029Sponsor estimatePhase 2NCT07421167A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in...Novartis Pharmaceuticals · Primary Immune Thrombocytopenia (ITP)RecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 17, 2028Sponsor estimatePhase 3NCT07357727A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Novartis Pharmaceuticals · Primary Myelofibrosis (PMF)RecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimateNo phase registeredNCT07598448A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNovartis Pharmaceuticals · Complement 3 GlomerulopathyRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 25, 2032Sponsor estimateNo phase registeredNCT07598422A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's SyndromeNovartis Pharmaceuticals · Schnitzler SyndromeRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2028Sponsor estimateNo phase registeredNCT07543419Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With...Novartis Pharmaceuticals · Hidradenitis SuppurativaRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2031Sponsor estimatePhase 2NCT07543120An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.Novartis Pharmaceuticals · Hypertension (HTN)RecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2027Sponsor estimatePhase 3NCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesNovartis Pharmaceuticals · Acute Coronary SyndromeActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2032Sponsor estimateNo phase registeredNCT06930859Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+)...Novartis Pharmaceuticals · Breast CancerRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2026ActualNo phase registeredNCT06606314Specified Drug-use Surveillance of Fabhalta CapsulesNovartis Pharmaceuticals · Paroxysmal Nocturnal HemoglobinuriaCompletedNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2026ActualPhase 1NCT06379217NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine...Novartis Pharmaceuticals · Metastatic Neuroendocrine Prostate CancerTerminatedNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2026ActualNo phase registeredNCT06275724Specified Drug-use Survey of Leqvio for s.c. Injection.Novartis Pharmaceuticals · Familial HypercholesterolaemiaCompletedNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2027Sponsor estimateNo phase registeredNCT05921994Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With...Novartis Pharmaceuticals · Hidradenitis SuppurativaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT05703516A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaNovartis Pharmaceuticals · Non-Small-Cell Lung CarcinomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2029Sponsor estimateNo phase registeredNCT05344469A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisNovartis Pharmaceuticals · Relapsing Multiple SclerosisRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 12, 2027Sponsor estimateNo phase registeredNCT05293470A Post Marketing Surveillance on Piqray in KoreaNovartis Pharmaceuticals · Breast CancerRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 10, 2027Sponsor estimatePhase 3NCT05030428Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseNovartis Pharmaceuticals · Atherosclerotic Cardiovascular DiseaseActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimateNo phase registeredNCT07945548A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine...Novartis Pharmaceuticals · Breast CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2030Sponsor estimatePhase 1NCT07908667A Study of TRB191 in Patients With Extensive-stage Small Cell Lung CancerNovartis Pharmaceuticals · Extensive-stage Small Cell Lung CancerRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2, 2032Sponsor estimatePhase 1/Phase 2NCT07190300TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With...Novartis Pharmaceuticals · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)RecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 16, 2027Sponsor estimatePhase 2NCT07047118A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant...Novartis Pharmaceuticals · Prostatic Cancer, Castration-ResistantActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2026Sponsor estimatePhase 2NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive...Novartis Pharmaceuticals · Metastatic Hormone-sensitive Prostate CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4,953 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner